scholarly journals Alemtuzumab As Therapy for Mixed Chimerism After Hematopoietic Stem Cell Transplantation for Fanconi Anemia (FA)

2013 ◽  
Vol 19 (2) ◽  
pp. S243-S244
Author(s):  
Sharat Chandra ◽  
Michael Grimley ◽  
Stella Davies ◽  
Kasiani Myers ◽  
Pooja Khandelwal ◽  
...  
Keyword(s):  
Stem Cell ◽  
Hematopoietic Stem Cell Transplantation ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Hematopoietic Stem Cell ◽  
Fanconi Anemia ◽  
Mixed Chimerism ◽  
Hematopoietic Stem

scholarly journals ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR ADULT PATIENTS WITH FANCONI ANEMIA.

2016 ◽  
Vol 8 ◽  
pp. 2016054 ◽  
Author(s):  
Hosein Kamranzadeh fumani ◽  
Mohammad Zokaasadi ◽  
Amir Kasaeian ◽  
Kamran Alimoghaddam ◽  
Asadollah Mousavi ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Stem Cell ◽  
Hematopoietic Stem Cell Transplantation ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Hematopoietic Stem Cell ◽  
Fanconi Anemia ◽  
Bone Marrow Failure ◽  
Term Survival ◽  
Hematopoietic Stem

Background & objectives: Fanconi anemia (FA) is a rare genetic disorder caused by an impaired DNA repair mechanism which leads to an increased tendency toward malignancies and progressive bone marrow failure. The only curative management available for hematologic abnormalities in FA patients is hematopoietic stem cell transplantation (HSCT). This study aimed to evaluate the role of HSCT in FA patients.Methods: Twenty FA patients with ages of 16 or more who underwent HSCT between 2002 and 2015 enrolled in this study. All transplants were allogeneic and the stem cell source was peripheral blood and all patients had a full HLA-matched donor.Results: Eleven patients were female and 9 male (55% and 45%). Mean age was 24.05 years. Mortality rate was 50% (n=10) and the main cause of death was GVHD. Survival analysis showed an overall 5-year survival of 53.63% and 13 year survival of 45.96 % among patients.Conclusion: HSCT is the only curative management for bone marrow failure in FA patients and despite high rate of mortality and morbidity it seems to be an appropriate treatment with an acceptable long term survival rate for adolescent and adult group.

Fanconi anemia in infancy: report of hematopoietic stem cell transplantation to a 13-month-old patient

2009 ◽  
Vol 89 (5) ◽  
pp. 722-723 ◽  
Author(s):  
Koichi Oshima ◽  
Akira Kikuchi ◽  
Shinji Mochizuki ◽  
Daisuke Toyama ◽  
Naoki Uchisaka ◽  
...  
Keyword(s):  
Stem Cell ◽  
Hematopoietic Stem Cell Transplantation ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Hematopoietic Stem Cell ◽  
Fanconi Anemia ◽  
Hematopoietic Stem

scholarly journals Atypical aggressive development of pigmented epithelioid melanocytoma in patient with Fanconi Anemia after hematopoietic stem cell transplantation

2020 ◽  
Vol 19 (2) ◽  
pp. 166-169
Author(s):  
S. A. Radygina ◽  
I. S. Kletskaya ◽  
I. O. Kostareva ◽  
K. V. Mitrakov ◽  
S. N. Kozlovskaya ◽  
...  
Keyword(s):  
Stem Cell ◽  
Hematopoietic Stem Cell Transplantation ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Hematopoietic Stem Cell ◽  
Fanconi Anemia ◽  
Distant Metastases ◽  
Melanocytic Lesion ◽  
Hematopoietic Stem ◽  
Regional Metastases

Pigmented epithelioid melanocytoma (PEM) is an uncommon, recently described melanocytic lesion. There is a high rate of regional metastases, but limited evidence of distant metastases, an indolent clinical course and favorable outcome. The article presents a clinical case of PEM with aggressive behavior and distant metastases in patient with Fanconi Anemia after hematopoietic stem cell transplantation. Parents gave their consent to use information about the child, including fotos, in the article.

scholarly journals Allogeneic Hematopoietic Stem Cell Transplantation in Fanconi Anemia

2021 ◽  
Vol 8 (9) ◽  
Author(s):  
Dumache R ◽  
◽  
Lascu A ◽  
Ciocan V ◽  
Muresan C ◽  
...  
Keyword(s):  
Stem Cell ◽  
Hematopoietic Stem Cell Transplantation ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Hematopoietic Stem Cell ◽  
Fanconi Anemia ◽  
Post Transplantation ◽  
Hematopoietic Stem ◽  
Blood Samples ◽  
The Impact

Objective: Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) is the treatment of choice in patients with Fanconi Anemia (FA). The aim of our study is to evaluate the impact and benefits of allogenic matched donor HSCT in a case of a 12 year-old girl with FA, who displayed good clinical evolution following 2 months post-transplantation. Patients and Methods: In the pre-transplant phase, reference blood samples from the donor and recipient were collected on EDTA. The DNA from blood samples was extracted using an automated Maxwell® 48 RSC instrument (Promega, USA) with the Maxwell® RSC Whole blood DNA kit (Promega, USA). For DNA quantification, the PowerQuant System kit (Promega, USA) was used with the ABI 7500 Real-time PCR system (Applied Biosystems, USA). The amplification of the short tandem repeat markers was performed using the 24plex Investigator QS kit (Qiagen, Germany) on a ProFlex PCR System. Furthermore, the PCR products were separated and detected on an ABI 3500 Genetic Analyzer (Applied Biosytems, USA). Results: After 30 days of the transplantation, a Complete Chimerism (CC) was achieved with a full replacement by donor derived hematopoietic cells. After 60 days of the transplantation, the CC status was maintained with improvement of hematological findings. Conclusion: In FA, chimerism monitoring after HSCT provides useful informations of engraftment or possibility of post-transplantation complications such as graft versus host disease.

Sign in / Sign up

Export Citation Format

Share Document